A5069061103- Advanced Breast Cancer Therapies
- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Cancer Treatment and Pharmacology
- Immune cells in cancer
- Cancer Cells and Metastasis
- Cancer-related Molecular Pathways
- Electrolyte and hormonal disorders
- PARP inhibition in cancer therapy
- Childhood Cancer Survivors' Quality of Life
- BRCA gene mutations in cancer
- Immune Cell Function and Interaction
- Immunotherapy and Immune Responses
- Chronic Lymphocytic Leukemia Research
- Glioma Diagnosis and Treatment
- Cancer Diagnosis and Treatment
- Inflammatory Biomarkers in Disease Prognosis
- Monoclonal and Polyclonal Antibodies Research
- Neuroendocrine Tumor Research Advances
- Neutropenia and Cancer Infections
- Lung Cancer Research Studies
- Multiple and Secondary Primary Cancers
- Nanoparticle-Based Drug Delivery
Hospital Universitario Virgen Macarena
2013-2024
GEICAM – Spanish Breast Cancer Group
2016-2024
Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla
2024
Universidad de Sevilla
2022
PURPOSE The OlympiA randomized phase III trial compared 1 year of olaparib (OL) or placebo (PL) as adjuvant therapy in patients with germline BRCA1/2, high-risk human epidermal growth factor receptor 2–negative early breast cancer after completing (neo)adjuvant chemotherapy ([N]ACT), surgery, and radiotherapy. patient-reported outcome primary hypothesis was that OL-treated may experience greater fatigue during treatment. METHODS Data were collected before random assignment, at 6, 12, 18, 24...
Abstract Purpose To evaluate the efficacy and safety of first-line therapy with palbociclib in a Spanish cohort treated after approval. Methods PALBOSPAIN is an observational, retrospective, multicenter study evaluating real-world patterns outcomes 1 L men women (any menopausal status) advanced HR + /HER2– BC diagnosed between November 2017 2019. The primary endpoint was progression-free survival (rw-PFS). Secondary endpoints included overall (OS), response rate (rw-RR), clinical benefit...
Febrile neutropenia (FN) is a common dose-limiting toxicity of chemotherapy, with profound impact on the evolution patients cancer, due to potential development serious complications, mortality, delays, and decrease in treatment intensity. This article seeks present an updated clinical guideline, recommendations regarding diagnosis, prevention, febrile adults solid tumors. The aspects covered include how properly approach risk microbial resistances, epidemiological aspects, considerations...
Abstract Background. The phase 3 PALLAS trial (NCT02513394) compared two years of the CDK4/6 inhibitor palbociclib with endocrine therapy provider choice, versus alone, as adjuvant treatment for patients Stage II-III hormone receptor-positive HER2-negative (HR+/HER2-) breast cancer. Genomic subtype (PAM50 intrinsic subtype) measured from whole-transcriptome RNA sequencing data was defined in protocol primary biomarker analysis prediction and prognosis. Clinical have been previously presented...
Hydroelectrolytic disorders are one of the most common metabolic complications in cancer patients. Although often alterations affecting various ions part manifestations oncological disease, even form paraneoplastic syndrome, we must not forget that very often, these could be caused by drugs, including some antineoplastic agents frequently used, such as platin derivatives or biologics. These guidelines review major management diagnosis, evaluation and treatment sodium, calcium, magnesium...
Hyponatremia (Na ˂135 mmol/l) is the most frequent electrolyte disorder in clinical practice, and syndrome of inappropriate antidiuretic hormone secretion (SIADH) commonest cause hyponatremia cancer patients. Correcting these patients can reduce morbidity mortality, increase response to anti-cancer agents, help hospital length stay costs. Tolvaptan an oral medication used treat SIADH-related that needs be initiated at so have their serum sodium monitored. If tolvaptan could day care units...
Infections are still a major cause of morbi-mortality in patients with cancer. Some these infections preventable through specific measures, such as vaccination or prophylaxis. This guideline aims to summarize the evidence and recommendations for prevention cancer patients, devoting special attention most prevalent infectious disease. All evidences will be graded according The Infectious Diseases Society America grading system.
Abstract Background We evaluated a new chemoimmunotherapy combination based on the anti-PD1 monoclonal antibody pembrolizumab and pyrimidine antimetabolite gemcitabine in HER2- advanced breast cancer (ABC) patients previously treated setting, order to explore potential synergism that could eventually obtain long term benefit these patients. Methods HER2-negative ABC received 21-day cycles of 200 mg (day 1) (days 1 8). A run-in-phase (6 + 6 design) was planned with two dose levels (DL) (1,250...
HER2-targeted therapies have dramatically improved outcomes of patients with HER2-positive breast cancer (BC), as demonstrated in neoadjuvant trials. This study aims to provide real-world evidence on the use and effectiveness combined pertuzumab, trastuzumab chemotherapy (CT) early-stage BC.
Abstract Background PALBOSPAIN (NCT04874025) is an observational, multicenter study evaluating real-world patterns and outcomes of first-line treatment with palbociclib plus endocrine therapy (ET) in routine clinical practice Spain. Results from progression-free survival (rwPFS) overall (OS) the total population, as well subgroup analysis according to sensitivity, age, menopausal status, location number metastatic sites have been previously reported. Here, we present prognostic impact...
Abstract Background Breast cancer (BC) is a clinically and biologically heterogenous disease where intrinsic subtypes play role. Non-luminal within HR+/HER2-negative do not benefit to the same extent from standard of care treatments as luminal subtypes. Thus, other strategies are needed. HER2-E subtype represents approximately 15.0% tumors in metastatic setting. According an exploratory analysis EGF30008 trial, advanced BC patients, despite presenting poor outcomes across treatments, showed...
Abstract INTRODUCTION AND OBJECTIVES Palbociclib associated with hormone therapy (HT) has shown significant benefit in progression-free survival (PFS) and response rate versus HT alone patients HR+, HER2- MBC. The PALBOSPAIN study evaluates the efficacy safety of palbociclib treatment under real-life conditions. main objective was to assess PFS, secondary objectives were overall (OS), rate, time next line treatment, percentage dose reduction safety. MATERIAL METHODS This is an observational,...
PALBOSPAIN is an observational, multicenter study to evaluate real-world practice patterns and outcomes of first-line treatment for advanced breast cancer (ABC) with Palbociclib. Results from progression free survival (rwPFS) overall (OS) in the total population according endocrine sensitivity have been previously reported. Here, we provide subgroup analysis age, sites number metastatic locations, menopausal status, dose received. Patients diagnosed HR+/HER2- ABC who had started palbociclib...
<title>Abstract</title> Background Limited data are available regarding the real-world effectiveness and safety of Cyclin Dependent Kinase 4/6 inhibitor (CDK4/6i) (palbociclib/ribociclib) just as a first-line treatment for patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2‒) metastatic breast cancer (MBC). Objective To assess whether clinical or demographic characteristics limit access to first line CDK4/6i in practice Autonomous Community...
CDK4/6i plus endocrine therapy (ET) is the standard of care for first-line in hormone receptor-positive (HR+)/HER2-negative (HER2−) mBC. However, resistance mechanisms appear and responses to this schedule may vary. Exceptionally, some patients still respond after 36 months. In addition, we previously showed that cell populations such as myeloid-derived suppressor cells (MDSCs) regulatory T (Treg) be promising targets mBC patients. Here, show evolution circulating MDSCs, Tregs, natural...
In the CLEOPATRA trial, pts with HER2+ PIK3CAmut ABC had a shorter progression-free survival (PFS) than those PIK3CAwt. We hypothesized that IPAT, an AKT inhibitor activity in PI3K/AKT-altered tumors, combined HP was both safe and effective ABC. IPATHER is open-label, single-arm, phase Ib trial evaluates safety efficacy of IPAT + candidates to maintenance following discontinuation first-line chemotherapy (CT) for reasons other progressive disease. The primary aim determine maximum tolerated...
Abstract Background Limited data are available regarding the real-world effectiveness and safety of Cyclin Dependent Kinase 4/6 inhibitor (CDK4/6i) (palbociclib/ribociclib) just as a first-line treatment for patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR + /HER2‒) metastatic breast cancer (MBC). Objective To assess whether clinical or demographic characteristics limit access to CDK4/6i in practice Autonomous Community Andalusia (Spain) between...